Legal Status
Legal Status
Notice
Government-Owned Inventions; Availability for Licensing
A Notice by the National Institutes of Health on
Document Details
Information about this document as published in the Federal Register.
- Printed version:
- Publication Date:
- 02/07/2003
- Agencies:
- National Institutes of Health
- Document Type:
- Notice
- Document Citation:
- 68 FR 6493
- Page:
- 6493 (1 page)
- Document Number:
- 03-2989
Document Details
-
Enhanced Content - Table of Contents
This tables of contents is a navigational tool, processed from the headings within the legal text of Federal Register documents. This repetition of headings to form internal navigation links has no substantive legal effect.
Enhanced Content - Table of Contents
-
Enhanced Content - Submit Public Comment
- This feature is not available for this document.
Enhanced Content - Submit Public Comment
-
Enhanced Content - Read Public Comments
- This feature is not available for this document.
Enhanced Content - Read Public Comments
-
Enhanced Content - Sharing
- Shorter Document URL
- https://www.federalregister.gov/d/03-2989 https://www.federalregister.gov/d/03-2989
Enhanced Content - Sharing
-
Enhanced Content - Document Tools
These tools are designed to help you understand the official document better and aid in comparing the online edition to the print edition.
-
These markup elements allow the user to see how the document follows the Document Drafting Handbook that agencies use to create their documents. These can be useful for better understanding how a document is structured but are not part of the published document itself.
Display Non-Printed Markup Elements
Enhanced Content - Document Tools
-
-
Enhanced Content - Developer Tools
This document is available in the following developer friendly formats:
- JSON: Normalized attributes and metadata
- XML: Original full text XML
- MODS: Government Publishing Office metadata
More information and documentation can be found in our developer tools pages.
Enhanced Content - Developer Tools
Published Document
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
National Institutes of Health, Public Health Service, DHHS.
ACTION:
Notice.
SUMMARY:
The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
ADDRESSES:
Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Recombinant SUMO-1 Isopeptidase Substrates for FRET Assays
Mary Dasso and Jun Hang (NICHD).
DHHS Reference No. E-086-02/0—Research Tool.
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426; shinnm@od.nih.gov.
The NIH announces a new Fluorescence Resonance Energy Transfer (FRET) assay for peptidases that regulate the processing of SUMO-1 and its removal from conjugation. SUMO-1 is an ubiquitin-like protein that becomes covalently linked to other proteins, which in turn may participate in events leading to cancer and viral infection. The inventors have created a FRET substrate that fuses unprocessed SUMO-1 at its N- and C-termini with different Green Fluorescence Protein (GFP) derivatives. The FRET assay may be used to identify pharmacological agents that can regulate the SUMO-1 peptidases or to monitor their activities.
Human Gene Critical to Fertility
Lawrence Nelson and Zhi-bin Tong (NICHD).
DHHS Reference No. E-239-00/1 filed 04 Apr 2001 (PCT/US01/10981).
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426; shinnm@od.nih.gov.
Some molecular pathways are unique to the reproductive process. Illuminating such processes would be expected to lead the way to the most specific molecular contraceptive targets. The Mater gene is essential for embryonic development beyond the two-cell stage. Mater expression is specific to the oocyte. Thus, Mater appears to qualify as a player in a unique molecular pathway that is specific to the reproductive process.
The human MATER gene was identified through research investigating autoimmune premature ovarian failure. Premature ovarian failure (POF) is a term used to describe a condition associated with female sex hormone deficiency and infertility in women younger than age 40. As many as 1% of all women in the United States are thought to be afflicted with POF. Autoimmunity is a well-established mechanism of premature ovarian failure.
The NIH announces a new technology that encompasses the MATER gene, protein and MATER-specific antibodies. These molecules can be used in diagnosing and/or treating infertility, and in developing contraceptives.
Anti-Inflammatory Actions of Cytochrome P450 Epoxygenase-derived Eicosanoids
Drs. Darryl C. Zeldin (NIEHS), James Liao (EM).
DHHS Reference Nos. E-252-1999/0-US-02 filed 09 Aug 2000 and E-252-1999/0-PCT-03 filed 10 Aug 2000.
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426; shinnm@od.nih.gov.
Cytochrome P450s catalyze the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species including humans. The eicosanoids are biosynthesized in numerous tissues including pancreas, intestine, kidney, heart, and lung where they are involved in many different biological activities.
The NIH announces a new therapy wherein epoxyeicosatrienoic acid (EET) compositions have been found to be useful in preventing endothelial cell death due to hypoxia-reoxygenation. Given that endothelial injury is an important early event in the development of the atherosclerotic plaque and is associated with myocardial dysfunction in ischemic heart disease, reduced EET levels are speculated to be involved in the pathogenesis of these cardiovascular disorders.
This research is described in Yang et al., Molecular Pharmacology 60: 310-320, 2001.
Start SignatureDated: January 29, 2003.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 03-2989 Filed 2-6-03; 8:45 am]
BILLING CODE 4140-01-P